Medin Technologies, Inc. Announces Appointment of Bob Baker as CEO

Medin Technologies, Inc. a leading orthopedic industry contract manufacturer, announced that Bob Baker has joined the company as Chief Executive Officer and a member of its board of directors.

Bob Baker joins Medin with an accomplished background in strategic, commercial and operational leadership in the orthopedic industry, having most recently served as Chief Executive Officer of Glebar Company, a leading manufacturer of advanced grinding machine systems for the medical device industry and other end markets. In his tenure at Glebar, Bob led a strategic transformation of the business, restructuring the company to address new market challenges, upgrading operations, and completing several strategic add-on acquisitions.

“I am honored to be joining Medin at such a pivotal moment for the orthopedic industry,” said Bob. “Demand for quality orthopedic products continues to increase as the market begins to address the backlog of elective procedures created by the global pandemic. Medin and AMT are well positioned to meet this global demand through optimized production and product diversification. This is an incredible opportunity and I look forward to working with this great team through the combined companies’ next phase of growth.”

“We are thrilled and excited to have Bob join the team as CEO for Medin and AMT,” said Mark Kammert, Partner of Seven Point Partners, LLC. “Bob has a proven track record in demonstrating outstanding leadership qualities and delivering exceptional value to customers. As Medin and AMT’s growth continues to accelerate in the post-COVID environment, we are confident that Bob is the right leader to expand market opportunity in medical contract manufacturing, while at the same time building on the company’s strong reputation for world class quality, product design, and customer responsiveness.”

Seven Point Partners LLC owns Medin Technologies and its sister company, AMT Medical, Inc.

“OEM customers in the medical device and orthopedic implant sector have necessarily high expectations in terms of quality, design and product delivery,” said Seven Point Managing Partner Tom Burchill. “Bob’s strong track record of commercial and operational excellence in the medical products industry is ideal to meet this need while simultaneously driving long-term revenue growth, profitability and outstanding outcomes for our valued customers.”

Prior to joining Glebar, Bob was Vice President, Operations at Stryker Corporation, in support of the Orthopedics Group. Previously, he was a Captain in the U.S. Army, serving in Iraq and Afghanistan.

Hot this week

Medtronic Expands AiBLE Spine Surgery Ecosystem with New Technologies and Siemens Healthineers Partnership

New advancements in the AiBLE Spine Surgery ecosystem build upon the company's commitment to procedural innovation and execution

Axlab, Danish Medtech Pioneer, expands to US with Advanced Robotic Tissue Sectioning for Pathology Laboratories

Kris Rokke, National Sales Director for Axlab in the US. "My team and I are extremely excited and honored about this unique opportunity to also offer this advanced technology to labs across the US and thus contribute to the pathology labs of tomorrow."

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.